Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic Pain Who Had an Inadequate Response to Pregabalin

Phase 2 Unknown 90 enrolled Haisco Pharmaceutical Group Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Investigate the efficacy and safety of HSK16149 capsule in Chinese patients with Diabetic Peripheral Neuropathic Pain (DPNP) who had an inadequate response to Pregabalin, following 4 weeks treatment in comparison to Pregabalin

Timeline

Start: 2024-04-19
Primary completion: 2024-07-12
Completion: 2024-07-14

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HSK16149	Unknown	20 mg	Oral
Subject	Pregabalin	Small molecule	150 mg	Oral

Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic Pain Who Had an Inadequate Response to Pregabalin

Summary

Timeline

Drugs

Indications